|63.00|| +0.65 / +1.04%|
Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following business divisions: Generic, Specialty Medicine, and Over-the-Counter (OTC). The Generic division involves the manufacture and sale of generic products such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The Specialty Medicine division provides products for central nervous system (CNS), respiratory system, women's health, oncology, and others. The OTC division offers medicines in categories such as cough and cold, allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications. Its products are manufactured under the Copaxone, Provigil, Azilect, Nuvigil, ProAir, Qvar, Treanda, Lonquex, Revascor, Milprosa, LeCette, Quartette, NexoBrid, and StemEx brand names. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
|Erez Vigodman||President, Chief Executive Officer & Director|
|Carlo de Notaristefani||President & CEO-Global Operations|
|Eyal Desheh||Chief Financial Officer & Group Executive VP|
|Michael R. Hayden||President-Global Research & Development|
|Eric Drapé||Executive Vice President & Head-Quality|